Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue: 2020-2021

Historic Current Deferred Revenue for Solid Biosciences (SLDB) over the last 2 years, with Dec 2021 value amounting to $8.1 million.

  • Solid Biosciences' Current Deferred Revenue fell 42.13% to $6.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $6.2 million, marking a year-over-year decrease of 42.13%. This contributed to the annual value of $8.1 million for FY2021, which is 61.00% down from last year.
  • Latest data reveals that Solid Biosciences reported Current Deferred Revenue of $8.1 million as of FY2021, which was down 61.00% from $20.7 million recorded in FY2020.
  • In the past 5 years, Solid Biosciences' Current Deferred Revenue ranged from a high of $20.7 million in FY2020 and a low of $8.1 million during FY2021.
  • In the last 2 years, Solid Biosciences' Current Deferred Revenue had a median value of $14.4 million in 2020 and averaged $14.4 million.
  • Data for Solid Biosciences' Current Deferred Revenue shows a maximum YoY tumbled of 61.00% (in 2021) over the last 5 years.
  • Over the past 2 years, Solid Biosciences' Current Deferred Revenue (Yearly) stood at $20.7 million in 2020, then crashed by 61.00% to $8.1 million in 2021.